Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Asthma
Interventions: Daclizumab; Drug
Lead sponsor: Facet Biotech; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 18
States / cities: Long Beach, California • Mission Viejo, California • San Diego, California + 14 more

Conditions: Pre-Eclampsia
Interventions: Human Albumin (colloid), Lactated Ringer's Injection (crystalloid), Edwards HemoSphere monitor with ClearSight-Acumen finger cuff; Drug · Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Rheumatoid Arthritis
Interventions: Etanercept, CHS-0214; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 647 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 37
States / cities: Phoenix, Arizona • Jonesboro, Arkansas • Anaheim, California + 32 more

Conditions: Hepatocellular Carcinoma, Cirrhosis, Liver Failure
Interventions: Branch Chain Amino Acid, maltodextrin; Drug · Other
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Opioid Use Disorder
Interventions: CHORUS+, Standard of care; Behavioral · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Stress
Interventions: Calm; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Type 2 Diabetes
Interventions: Glipizide, Glipizide and Glargine; Drug
Lead sponsor: Cook County Health; Government
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Aging, Sarcopenia
Interventions: Peanut Protein Powder, Full body resistance training; Dietary Supplement · Behavioral
Lead sponsor: Auburn University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Metastatic Breast Cancer
Interventions: Pertuzumab, Placebo, Trastuzumab, Docetaxel; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 808 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 159
States / cities: Scottsdale, Arizona • Jonesboro, Arkansas • Alhambra, California + 120 more

Conditions: Bone Health, Cognitive Health
Interventions: Whole egg powder, Whole milk powder, Gelatin food product; Other
Lead sponsor: University of Georgia; Other
Eligibility: 9 Years to 13 Years
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: Diastolic Dysfunction, Hypertension
Interventions: Valsartan; Drug
Lead sponsor: Novartis; Industry
Eligibility: 45 Years and older
Enrollment: 317 participants
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Renal Insufficiency, Chronic, Hyperkalemia
Interventions: Sodium Zirconium Cyclosilicate (SZC), Placebo, Lisinopril, Valsartan, Irbesartan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 42
States / cities: Surprise, Arizona • Tucson, Arizona • Canyon Country, California + 36 more

Conditions: Cirrhosis, Hepatic Encephalopathy
Interventions: Placebo, VE303, oral vancomycin; Drug
Lead sponsor: Patricia Bloom; Other
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Type 2 Diabetes
Interventions: Cagrilintide, Semaglutide, Tirzepatide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,024 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 117
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 96 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Tirzepatide, Insulin Degludec; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 33
States / cities: Little Rock, Arkansas • Fresno, California • Huntington Park, California + 28 more

Conditions: Non-small Cell Lung Cancer
Interventions: Divarasib, Pembrolizumab, Nivolumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 6
States / cities: Clovis, California • Atlanta, Georgia • Farmington Hills, Michigan + 2 more

Conditions: Rheumatoid Arthritis
Interventions: Fostamatinib and placebo injections, Adalimumab and placebo of fostamatinib, Placebo of fostamatinib, fostamatinib, and placebo injections; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 644 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 40
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 37 more

Conditions: Lupus Erythematosus, Systemic
Interventions: Rituximab, Placebo, Prednisone, Acetaminophen, Diphenhydramine; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 63
States / cities: Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 51 more

Conditions: Pancreatic Neoplasms, Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer, Pancreas Neoplasms, Adenocarcinoma
Interventions: Gemcitabine, nab-paclitaxel, Pharmacological ascorbate; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Muscle Synthesis
Interventions: Protein Blend; Other
Lead sponsor: DuPont Nutrition and Health; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Elevated S-adenosylhomocysteine
Interventions: Alpha-GPC, Creatine and Ashwagandha (Sensoril®), Placebo; Dietary Supplement · Other
Lead sponsor: Standard Process Inc.; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: South Gate, California

Conditions: Spinal Cord, Metabolic Syndrome, Diabetes
Interventions: LC/HP; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Liver Transplantation, Metabolic Syndrome X, Obesity
Interventions: Control group, Mediterranean diet, Protein-Sparing Modified Fast (PSMF); Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Type 2 Diabetes Mellitus
Interventions: Sotagliflozin, Insulin glargine (HOE901), Placebo, Oral Antidiabetes Drugs (OADs); Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 571 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Mesa, Arizona • Phoenix, Arizona • Huntington Park, California + 42 more

Search by objective public record fields.

Study of Daclizumab in Patients With Chronic, Persistent Asthma

Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia

Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)

Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma

PrEP and MOUD Rapid Access for Persons Who Inject Drugs: The CHORUS+ Study

Calm College: A Brief Mobile App Meditation Intervention Among Stressed College Students

Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA

Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults

A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer

Skeletal and Cognitive Effects of Nutrition From Eggs

To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

VE303 for Treatment of Hepatic Encephalopathy (HE)

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)

Protein Blends (Soy, Whey and Casein) for Muscle Synthesis

Role of a Dietary Supplement in Lowering SAH in Healthy Adults With Elevated Plasma SAH and Normal Homocysteine Levels

Low Carbohydrate/High Protein Diet to Improve Metabolic Health

Mediterranean Diet and Protein-Sparing Modified Diet for Metabolic Syndrome in Liver Transplant Recipients

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents